Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.
Tessellate BIO has raised $8.5M in total funding. The most recent round was Seed. The last funding was announced in October 2023.
Tessellate BIO's investors include Forbion Capital Partners, BioGeneration Ventures.
Tessellate BIO is headquartered in Naarden, The Netherlands.
Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.
Tessellate BIO is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tessellate BIO — Funding & Investors." VCBacked, October 17, 2023, https://www.vcbacked.co/company/tessellate-bio. Accessed September 29, 2026.
VCBacked. (2023). Tessellate BIO — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/tessellate-bio
{{cite web |title=Tessellate BIO — Funding & Investors |url=https://www.vcbacked.co/company/tessellate-bio |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated